June 1, 2023 10:19 AM EDTUpdated 04:00 PM
R&D
FDA+

FDA lifts hold on Mol­e­c­u­lar Tem­plates’ mul­ti­ple myelo­ma tri­al af­ter less than two months

Lei Lei Wu

News Reporter

The FDA has lift­ed a par­tial clin­i­cal hold on Mol­e­c­u­lar Tem­plates’ ear­ly-stage tri­al for a mul­ti­ple myelo­ma drug, the biotech com­pa­ny

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

TRENDING NOW

Lil­ly shuf­fles key ex­ec­u­tive po­si­tions; Mikael Dol­sten takes an­oth­er post-Pfiz­er as­sign­ment

Io­vance stock plum­mets af­ter low­ered full-year guid­ance, missed an­a­lyst ex­pec­ta­tions for Am­tagvi

Rev­o­lu­tion’s KRAS drugs ap­pear com­pet­i­tive in sev­er­al lung can­cer set­tings

From deal to dis­as­ter: Drug­mak­ers face a changed Wash­ing­ton as Trump em­braces ‘most fa­vored na­tion’ prices

Lon­za says its US-based sites are in high de­mand as phar­ma tar­iffs near

sponsored

In one of the riski­est in­dus­tries — Biotech — a sure­fire way to neu­tral­ize some of that risk emerges

A service from the Financial Times